Grants
Apply for a Grant
The VHL Alliance (VHLA) is committed to finding a cure for Von Hippel-Lindau (VHL) disease through research, education, and patient support. As the largest source of funding for VHL research worldwide, the VHLA has awarded over $3,000,000 in research grants since its founding. VHLA’s Competitive Research Grant Program supports groundbreaking research that aims to advance our understanding of VHL disease, improve detection and treatment options, and, ultimately, find a cure.
The VHLA awards three types of grants annually: one (1) Pilot Grant, one (1) Research Grant, and two (2) Postdoctoral Fellowship Grants.
International applicants are welcome to apply.
Grant Mechanisms
- Who Can Apply: New and existing VHL researchers, including those exploring innovative ideas and approaches to VHL diagnosis, treatment, or prevention.Pilot Grant$25k
Purpose: This grant encourages researchers to explore important issues in VHL and pursue paradigm-shifting ideas. The goal is to foster new research directions that could significantly impact VHL care.
Funding: $25,000 for one year.
Deadlines: November 1, 2024 (Letter of Intent); January 17, 2025 (Full application, by invitation only). - Who Can Apply: Researchers aiming to contribute new insights into the basic biology of VHL disease, improve early detection, or develop new treatments.Research Grant$100k over two years
Purpose: To support studies that will offer meaningful contributions to VHL research, focusing on understanding the disease at a fundamental level and developing new diagnostic and therapeutic strategies.
Funding: $100,000 over two years.
Deadlines: November 1, 2024 (Letter of Intent); January 17, 2025 (Full application, by invitation only). - Who Can Apply: Promising postdoctoral scientists with ≤ 3 years of experience who are committed to careers focused on VHL research.Postdoctoral Fellowship Grant$100k over two years
Purpose: This grant is designed to attract and support postdoctoral researchers dedicated to the study of VHL and to build a pipeline of future leaders in the field of VHL research.
Funding: $100,000 over two years.
Deadlines: November 1, 2024 (Letter of Intent); January 17, 2025 (Full application, by invitation only).
Application & Peer Review Process
The VHLA grant application process follows a structured pathway to ensure that only the highest-quality proposals are considered for funding. Below is a detailed overview of the process:
Letter of Intent (LOI):
All interested applicants must submit an LOI by November 1, 2024. The LOI should not exceed one page and must include:
Name of the principal investigator (PI).
– Brief description of the PI’s qualifications to undertake the proposed project.
– The type of award being sought (Pilot, Research, or Postdoctoral Fellowship).
– A brief project description that emphasizes relevance to VHL, including background, hypothesis, specific aims, and impact on VHL patient care.
– For Postdoctoral Fellowship applicants: Please also include the name and qualifications of the mentor under whose guidance the research will be conducted.
LOIs should be submitted via email to [email protected].
Full Application Submission:
LOIs will undergo peer review, and applicants will be notified of their status (either rejected or advanced) by November 17, 2024. Full applications will be accepted by invitation only and must be submitted by January 17, 2025.
Peer Review Process:
Full applications will be reviewed in a session on March 11, 2025, by a panel of experts in VHL research. The review will assess scientific merit, relevance to VHLA’s mission, and potential for significant impact on VHL patient care.
Grantee Announcement:
Successful applicants will be notified of their award by April 11, 2025.
Project Start Date:
The earliest project start date for awarded grants is May 1, 2025.
2024 Research Grant Dates and Deadlines:
August 30, 2024: Grant Invitation Emailed
November 1, 2024: Letter of Intent Deadline
November 17, 2024: LOI Applicants Notified of Status
January 17, 2025: Application Deadline
March 11, 2025: Grant Application Review Session
April 11, 2025: Grantee Announcement
May 1, 2025: Earliest Project Start Date
Additional Funding Opportunities
Previous Grant Recipients
Dr. Samra Turajlic, Francis Crick Institute (UK)
Dr. Mei Yee Koh, University of Utah (US)
Dr. Reut Halperin, ENTIRE Research Center (Israel)
John Chappell, PhD, Fralin Biomedical Research Institute at Virginia Tech Carilion
Alessandro Larcher, MD, IRCCS Ospedale San Raffaele
Patricia Dahia MD, PhD, University of Texas Health Science Center at San Antonio
Alice Soragni, PhD, UCLA David Geffen School of Medicine
Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center
Amit Tirosh, MD, Sheba Medical Center
David Zagzag, MD, PHD, NYU Langone Medical Center
Bettie Gardie PhD, INSERM (Institut national de la Sante et de la Recherche Medicale)
Anna Matynia, PhD, Stein Eye Institute, UCLA, Los Angeles
Barbara A. Mysona PhD, Augusta University
Othon Iliopoulos, MD, PhD Massachusetts General Hospital
Raymond Kim, MD, PhD University of Toronto
Haifeng Yang PhD, Thomas Jefferson University
Ruhee Dure, PhD, Baylor College of Medicine
Dhaval Patel, MD, NIH, National Cancer Institute
Michael B. Gorin, MD, PhD, University of California
Raymond Kim, MD, PhD, University of Toronto
Ian Frew, PhD, University of Zurich, Switzerland
A.N.A. van der Horst-Schrivers, MD, PhD, University Medical Center Groningen in The Netherlands
Othon Iliopoulos, MD, PhD, Massachusetts General Hospital
Daniel Segal, PhD, Tel Aviv University
Eamonn R. Maher, MD, FRCP, University of Birmingham
Haifeng Yang, PhD, Cleveland Clinic
Brenda Petrella, PhD, Dartmouth Medical School
Rachel Giles, PhD, University Medical Center Utrecht
Thera P. Links, MD, PhD, University Medical Centre Groningen
Thera P. Links, MD, PhD, University Medical Centre Groningen
James Handa, MD, Johns Hopkins University School of Medicine
Rupal Bhatt, MD, PhD, Beth Israel Deaconess Medical Center
Armin Pause, PhD, McGill Universit
Bin Teh, MD, PhD, Van Andel Institute
Donald Bellgrau, PhD, University of Colorado, Denver
Donald Bellgrau, PhD, University of Colorado, Denver
George V. Thomas, MD, Oregon Health and Science University’s Knight Cancer Institute
Robert Weiss, MD, University of California
Susanne Schlisio, PhD, Ludwig Institute for Cancer
W. Kimryn Rathmell, MD, PhD, University of North Carolina
Shufen Chen, MD, PhD, University of North Carolina
Ian Frew, PhD, University of Zurich
Andrea Ruxandra-Schmitzer, PhD, University of Montreal
Judith Frydman, PhD, Stanford University
Judith Frydman, PhD, Stanford University
Michael Zimmer, PhD, Massachusetts General Hospital
Daniel J. George, MD, Duke University Medical Center
Daniel J. George, MD, Duke University Medical Center
Tien Hsu, PhD, Boston University Medical Center
Pierre Jacomet, MD, Catholic University Medical Center
Maria Czyzyk-Krzeska, MD, PhD, University of Cincinnati
Robert J. Duronio, PhD, University of North Carolina
Maria Czyzyk-Krzeska, MD, PhD, University of Cincinnati
Robert J. Duronio, PhD, University of North Carolina
Shahriar Koochekpour, MD, PhD, Louisiana State University Health Sciences Center
Ehud Gazit, PhD, Tel Aviv University
Maria Czyzyk-Krzeska, MD, PhD, University of Cincinnati
Shahriar Koochekpour, MD, PhD, Louisiana State University Health Sciences Center
James R. Gnarra, PhD, University of Pittsburgh Medical Center
James R. Gnarra, PhD, University of Pittsburgh Medical Center
Robert D. Burk, MD, Albert Einstein College of Medicine of Yeshiva University